{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:38:37Z","timestamp":1789047517532,"version":"build-2803163510"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Immunology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.molimm.2025.04.016","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T22:31:27Z","timestamp":1746484287000},"page":"56-71","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Goals and strategies in vaccine development against tuberculosis"],"prefix":"10.1016","volume":"183","author":[{"given":"Bidyarani Devi","family":"Konjengbam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikrujam Nilkanta","family":"Meitei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2994-9493","authenticated-orcid":false,"given":"Reena","family":"Haobam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molimm.2025.04.016_bib1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2249.2012.04614.x","article-title":"Is interferon-gamma the right marker for Bacille Calmette-Gu\u00e9rin-induced immune protection? The missing link in our understanding of Tuberculosis immunology","volume":"169","author":"Abebe","year":"2012","journal-title":"Clin. Exp. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2016.10","article-title":"Updates on the risk factors for latent Tuberculosis reactivation and their managements","volume":"5","author":"Ai","year":"2016","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.molimm.2025.04.016_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-11851-z","article-title":"Designing a novel multi\u2011epitope vaccine against Ebola virus using reverse vaccinology approach","volume":"12","author":"Alizadeh","year":"2022","journal-title":"Sci. Rep.."},{"key":"10.1016\/j.molimm.2025.04.016_bib4","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.csbj.2023.01.019","article-title":"In silico design of a promiscuous chimeric multi-epitope vaccine against Mycobacterium tuberculosis","volume":"21","author":"Andongma","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.molimm.2025.04.016_bib5","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1080\/07391102.2020.1850357","article-title":"Design of a multi-epitope based vaccine targeting M-Protein of SARS-CoV2: an immunoinformatics approach","volume":"40","author":"Ayyagari","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.molimm.2025.04.016_bib6","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/08830185.2019.1657426","article-title":"Immunoinformatics: In silico approaches and computational design of a multi-epitope, immunogenic protein","volume":"38","author":"Bahrami","year":"2019","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib7","series-title":"In Infectious Diseases Drug Delivery Systems","first-page":"147","article-title":"Nanotechnology-based vaccination for TB","author":"Barik","year":"2023"},{"key":"10.1016\/j.molimm.2025.04.016_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-80899-6","article-title":"In silico analysis of epitope-based vaccine candidate against Tuberculosis using reverse vaccinology","volume":"11","author":"Bibi","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molimm.2025.04.016_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.tube.2015.11.008","article-title":"KLRG1 and PD-1 expression are increased on T-cells following Tuberculosis-treatment and identify cells with different proliferative capacities in BCG-vaccinated adults","volume":"97","author":"Boer","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.molimm.2025.04.016_bib10","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1286-4579(99)80033-1","article-title":"\u03b4 T cells and Mycobacterium tuberculosis","author":"Boom","year":"1999","journal-title":"Microbes Infect."},{"key":"10.1016\/j.molimm.2025.04.016_bib11","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1128\/IAI.69.4.2714-2717.2001","article-title":"Boosting vaccine for Tuberculosis","volume":"69","author":"Brooks","year":"2001","journal-title":"Infect. Immun."},{"key":"10.1016\/j.molimm.2025.04.016_bib12","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.tube.2006.01.024","article-title":"RUTI: A new chance to shorten the treatment of latent tuberculosis infection","volume":"86","author":"Cardona","year":"2006","journal-title":"Tuberculosis"},{"key":"10.1016\/j.molimm.2025.04.016_bib13","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/s41423-020-0502-z","article-title":"New insights into the evasion of host innate immunity by Mycobacterium tuberculosis","volume":"17","author":"Chai","year":"2020","journal-title":"Cell. Mol. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib14","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7150\/ntno.19796","article-title":"Nanoparticle vaccines adopting virus-like features for enhanced immune potention","volume":"1","author":"Chattopadhyay","year":"2017","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.molimm.2025.04.016_bib15","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/acs.molpharmaceut.1c00447","article-title":"Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines","volume":"18","author":"Chatzikleanthous","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molimm.2025.04.016_bib16","first-page":"1","article-title":"Nanoscale peptide self-assemblies boost BCG-primed cellular immunity against Mycobacterium tuberculosis","author":"Chesson","year":"2018","journal-title":"Sci. Rep.."},{"key":"10.1016\/j.molimm.2025.04.016_bib17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2172-13-13","article-title":"Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis","volume":"13","author":"Chodisetti","year":"2012","journal-title":"BMC Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1600-065X.2008.00702.x","article-title":"The role of cytokines in the initiation, expansion, and control of cellular immunity to Tuberculosis","author":"Cooper","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.molimm.2025.04.016_bib19","doi-asserted-by":"crossref","DOI":"10.1146\/annurev.immunol.021908.132703","article-title":"Cell-mediated immune responses in Tuberculosis","author":"Cooper","year":"2009","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib20","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1128\/CVI.00271-15","article-title":"A synthetic long peptide derived from Mycobacterium tuberculosis latency antigen Rv1733c protects against tuberculosis","volume":"22","author":"Coppola","year":"2015","journal-title":"Clin. Vaccin. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2019.02806","article-title":"BCG-induced cross-protection and development of trained immunity: implication for vaccine design","volume":"10","author":"Covi\u00e1n","year":"2019","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijid.2014.11.026","article-title":"Tuberculosis vaccines - state of the art, and novel approaches to vaccine development","volume":"32","author":"Da Costa","year":"2015","journal-title":"Int. J. Infect. Dis.."},{"key":"10.1016\/j.molimm.2025.04.016_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41586-019-1817-8","article-title":"Prevention of tuberculosis in macaques after intravenous BCG immunization","author":"Darrah","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2025.04.016_bib24","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.4049\/jimmunol.1101122","article-title":"Functional capacity of Mycobacterium tuberculosis-specific T cell responses in humans is associated with mycobacterial load","volume":"187","author":"Day","year":"2011","journal-title":"J. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018773","article-title":"Latency antigen \u03b1-crystallin based vaccination imparts a robust protection against TB by modulating the dynamics of pulmonary cytokines","volume":"6","author":"Dey","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.molimm.2025.04.016_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01134","article-title":"What have we learnt about BCG vaccination in the last 20 Years?","volume":"8","author":"Dockrell","year":"2017","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000363321","article-title":"Natural Killer Cells: A coherent model for their functional role in Mycobacterium tuberculosis infection","author":"Esin","year":"2015","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.molimm.2025.04.016_bib28","first-page":"1621","article-title":"Phase 2b controlled trial of M72\/AS01E vaccine to prevent Tuberculosis","author":"Evans","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2025.04.016_bib29","first-page":"0024","article-title":"Tuberculosis vaccine: A journey from BCG to present","author":"Fatima","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.molimm.2025.04.016_bib30","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/infdis\/jit267","article-title":"A heterologous prime\/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus","volume":"208","author":"Fournillier","year":"2013","journal-title":"J. Infect. Dis.."},{"key":"10.1016\/j.molimm.2025.04.016_bib31","first-page":"263","article-title":"Where are we going, where have we been?","author":"Frick","year":"2013","journal-title":"HIV, HCV, TB Pipeline Rep."},{"key":"10.1016\/j.molimm.2025.04.016_bib32","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1016\/j.vaccine.2009.06.093","article-title":"A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge","volume":"27","author":"Gao","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.016_bib33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10989-022-10406-0","article-title":"An immunoinformatic strategy to develop new Mycobacterium tuberculosis multi-epitope vaccine","volume":"28","author":"Ghandadi","year":"2022","journal-title":"Int. J. Pept. Res. Ther.."},{"key":"10.1016\/j.molimm.2025.04.016_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01803","article-title":"MTBVAC: attenuating the human pathogen of Tuberculosis (TB) toward a promising vaccine against the TB epidemic","volume":"8","author":"Gonzalo-Asensio","year":"2017","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.molmed.2012.07.008","article-title":"Lipidated promiscuous peptides vaccine for tuberculosis-endemic region regions","volume":"18","author":"Gowthaman","year":"2012","journal-title":"Trends Mol. Med"},{"key":"10.1016\/j.molimm.2025.04.016_bib36","doi-asserted-by":"crossref","first-page":"389","DOI":"10.3109\/1040841X.2013.859125","article-title":"Challenges and solutions for a rational vaccine design for TB-endemic regions","volume":"41","author":"Gowthaman","year":"2015","journal-title":"Crit. Rev. Microbiol"},{"key":"10.1016\/j.molimm.2025.04.016_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039215","article-title":"\u2018Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for Tuberculosis and underlying immune responses in the lung\u2019","volume":"7","author":"Gupta","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.molimm.2025.04.016_bib38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1196\/annals.1358.010","article-title":"The immune response to BCG vaccination of newborns","volume":"1062","author":"Hanekom","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.molimm.2025.04.016_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(08)61036-3","article-title":"Tuberculosis vaccine development: goals, immunological design, and evaluation","volume":"372","author":"Hoft","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.molimm.2025.04.016_bib40","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1080\/21645515.2017.1335374","article-title":"Efficacy of Mycobacterium vaccae immunotherapy for patients with Tuberculosis: a systematic review and meta-analysis","volume":"13","author":"Huang","year":"2017","journal-title":"Hum. Vaccin. Immunother.."},{"key":"10.1016\/j.molimm.2025.04.016_bib41","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2011.07.039","article-title":"Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis","volume":"29","author":"Hubbell","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.016_bib42","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.tube.2016.03.006","article-title":"Current perspective in tuberculosis vaccine development for high TB endemic regions","author":"Husain","year":"2016","journal-title":"Tuberculosis"},{"key":"10.1016\/j.molimm.2025.04.016_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.ppat.1005490","article-title":"TIM3 mediates T cell exhaustion during Mycobacterium tuberculosis infection","volume":"12","author":"Jayaraman","year":"2016","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.molimm.2025.04.016_bib44","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/infdis\/jiw467","article-title":"Induction of an immunoprotectiveT-cell repertoire with diverse genetic coverage by a novel viral-vectored tuberculosis vaccine in humans","volume":"214","author":"Jeyanathan","year":"2016","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.molimm.2025.04.016_bib45","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1021\/acs.molpharmaceut.6b00434","article-title":"Adjuvanticity regulation by biodegradable polymeric nano\/microparticle size","volume":"14","author":"Jia","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.molimm.2025.04.016_bib46","article-title":"Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trials","author":"Joan","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.016_bib47","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.1016\/j.vaccine.2015.06.051","article-title":"First-in-human trial of the post-exposure Tuberculosis vaccine H56: IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults","volume":"33","author":"Kany","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.molimm.2025.04.016_bib48","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2012.03.004","article-title":"Tuberculosis vaccine development: strength lies in tenacity","volume":"33","author":"Kaufmann","year":"2012","journal-title":"Trends Immunol."},{"issue":"12","key":"10.1016\/j.molimm.2025.04.016_bib49","article-title":"Vaccine development against tuberculosis over the last 140 years: failure as part of success","volume":"6","author":"Kaufmann","year":"2021","journal-title":"Front. Microbiol"},{"key":"10.1016\/j.molimm.2025.04.016_bib50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ijid.2016.10.018","article-title":"Novel approaches to tuberculosis vaccine development","volume":"56","author":"Kaufmann","year":"2017","journal-title":"Int. J. Inf. Dis."},{"key":"10.1016\/j.molimm.2025.04.016_bib51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd.2017.162","article-title":"Host-directed therapies for bacterial and viral infections","volume":"17","author":"Kaufmann","year":"2018","journal-title":"Nat. Rev. Drug Discov.."},{"key":"10.1016\/j.molimm.2025.04.016_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms9533","article-title":"Mucosal vaccination with attenuated Mycobacterium tuberculosis induces strong central memory responses and protects against Tuberculosis","volume":"6","author":"Kaushal","year":"2015","journal-title":"Nat. Commun.."},{"key":"10.1016\/j.molimm.2025.04.016_bib53","article-title":"Distinct strategies employed by dendritic cells and macrophages in restricting Mycobacterium tuberculosis infection: different philosophies but same desire","volume":"0185","author":"Khan","year":"2016","journal-title":"Int. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.molimm.2025.04.016_bib54","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.4049\/jimmunol.0903002","article-title":"Metabolic shifts in immunity and inflammation","volume":"184","author":"Kominsky","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2018.02637","article-title":"Neutrophils: innate effectors of TB resistance","volume":"9","author":"Kroon","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2025.04.016_bib56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016709","article-title":"BCG vaccination: a role for vitamin D?","volume":"6","author":"Lalor","year":"2011","journal-title":"PloS One"},{"key":"10.1016\/j.molimm.2025.04.016_bib57","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s10096-020-03843-6","article-title":"Tuberculosis vaccine development: from classic to clinical candidates","volume":"39","author":"Li","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.molimm.2025.04.016_bib58","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1128\/CVI.05700-11","article-title":"A novel Tuberculosis DNA vaccine in an HIV-1 P24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1","volume":"19","author":"Li","year":"2012","journal-title":"Clin. Vaccin. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib59","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.gt.3301908","article-title":"Single dose of a vaccine based on DNA encoding mycobacterial hsp65 protein plus TDM-loaded PLGAmicrospheres protects mice against a virulent strain of Mycobacterium tuberculosis","volume":"10","author":"Lima","year":"2003","journal-title":"Gene Ther."},{"key":"10.1016\/j.molimm.2025.04.016_bib60","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201701395","article-title":"Advances and opportunities in nanoparticle-and nanomaterial-based vaccines against bacterial infections","volume":"7","author":"Lin","year":"2018","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.molimm.2025.04.016_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2172-6-4","article-title":"The mannose receptor is expressed by subsets of APC in non-lymphoid organs","volume":"6","author":"Linehan","year":"2005","journal-title":"BMC Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00903","article-title":"Differential effect of viable versus necrotic neutrophils on Mycobacterium tuberculosis growth and cytokine induction in whole blood","volume":"9","author":"Lowe","year":"2018","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib63","first-page":"1","article-title":"A functional role for antibodies in Tuberculosis","author":"Lu","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.molimm.2025.04.016_bib64","article-title":"Heterologous prime-boost vaccination","volume":"21","author":"Lu","year":"2009","journal-title":"CurrOpin Immunol."},{"issue":"1","key":"10.1016\/j.molimm.2025.04.016_bib65","first-page":"53","article-title":"History of BCG vaccine","volume":"8","author":"Luca","year":"2013","journal-title":"A J. Clin. Med."},{"key":"10.1016\/j.molimm.2025.04.016_bib66","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1080\/10717544.2022.2120565","article-title":"Nanomaterials in Tuberculosis DNA vaccine delivery: historical perspective and current landscape","volume":"29","author":"Luo","year":"2022","journal-title":"Drug Deliv."},{"key":"10.1016\/j.molimm.2025.04.016_bib67","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/14760584.7.5.635","article-title":"Tuberculosis: vaccines in the pipeline","volume":"7","author":"Ly","year":"2008","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.molimm.2025.04.016_bib68","article-title":"Prevention of Mycobacterium tuberculosis infection with H4:IC31 vaccine or BCG revaccination","author":"Mabwe","year":"2018","journal-title":"N. Engl. J.Med"},{"key":"10.1016\/j.molimm.2025.04.016_bib69","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1183\/09031936.00120908","article-title":"LTBI: latent Tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET Consensus Statement","volume":"33","author":"Mack","year":"2009","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.molimm.2025.04.016_bib70","doi-asserted-by":"crossref","first-page":"6843","DOI":"10.4049\/jimmunol.162.11.6843","article-title":"Helminth- and Bacillus Calmette-Gu\u00e9rin-induced immunity in children sensitized in utero to filariasis and schistosomiasis","volume":"162","author":"Malhotra","year":"1999","journal-title":"J. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib71","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.191.2.287","article-title":"Inhibition of Ca2+\u2009signaling by Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and increased survival within human macrophages","volume":"191","author":"Malik","year":"2000","journal-title":"J. Exp. Med.."},{"issue":"4","key":"10.1016\/j.molimm.2025.04.016_bib72","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.4049\/jimmunol.163.4.2249","article-title":"Newborns develop a Th1-type immune response to Mycobacterium bovis Bacillus Calmette-Gu\u00e9rin vaccination","volume":"163","author":"Marchant","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib73","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.micinf.2005.03.009","article-title":"Prime-boost immunization strategies for tuberculosis","author":"Mcshane","year":"2005","journal-title":"Microbes Infect."},{"issue":"3","key":"10.1016\/j.molimm.2025.04.016_bib74","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1007\/s11033-022-08158-7","article-title":"Polymorphisms in drug metabolism genes as a risk factor for first-line anti-tuberculosis drug-induced liver injury","volume":"50","author":"Meitei","year":"2023","journal-title":"Mol. Bio Rep."},{"key":"10.1016\/j.molimm.2025.04.016_bib75","doi-asserted-by":"crossref","first-page":"12434","DOI":"10.1073\/pnas.0703510104","article-title":"Poor correlation between BCG vaccination-induced T cell responses and protection against Tuberculosis","volume":"104","author":"Mittr\u00fccker","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molimm.2025.04.016_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00407","article-title":"Immune responses to Bacillus Calmette-Gu\u00e9rin vaccination: why do they fail to protect against Mycobacterium tuberculosis?","volume":"8","author":"Moliva","year":"2017","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib77","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s12026-022-09284-x","article-title":"Reverse vaccinology approach to design a multi-epitope vaccine construct based on the Mycobacterium tuberculosis biomarker PE_PGRS17","volume":"70","author":"Moodley","year":"2022","journal-title":"Immunol. Res."},{"key":"10.1016\/j.molimm.2025.04.016_bib78","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1002\/adma.201200446","article-title":"Engineering nano-and microparticles to tune immunity","volume":"24","author":"Moon","year":"2012","journal-title":"Adv. Mater."},{"key":"10.1016\/j.molimm.2025.04.016_bib79","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.31.1_supplement.938.5","article-title":"Inulin acetate nanoparticles as vaccine adjuvants","volume":"31","author":"Narisetty","year":"2017","journal-title":"FASEB J."},{"key":"10.1016\/j.molimm.2025.04.016_bib80","article-title":"immunogenicity, and efficacy of the candidate Tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial","volume":"3","author":"Ndiaye","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.molimm.2025.04.016_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.944183","article-title":"Progressive host-directed strategies to potentiate BCG vaccination against Tuberculosis","volume":"13","author":"Negi","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib82","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1714021","article-title":"Prevention of M. tuberculosis infection with H4:IC31 vaccine or BCG revaccination","volume":"379","author":"Nemes","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molimm.2025.04.016_bib83","article-title":"DNA vaccines against tuberculosis","author":"Nicolas","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.molimm.2025.04.016_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2017.01147","article-title":"The recombinant Bacille Calmette-Gu\u00e9rin vaccine VPM1002: ready for clinical efficacy testing","volume":"8","author":"Nieuwenhuizen","year":"2017","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib85","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/nri2708","article-title":"Physiological and pathological roles for microRNAs in the immune system","volume":"10","author":"O\u2019Connell","year":"2010","journal-title":"Nat. Rev. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib86","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1586\/erv.10.89","article-title":"Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses","volume":"9","author":"Oyewumi","year":"2010","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.molimm.2025.04.016_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14433-7","article-title":"Nitric oxide orchestrates metabolic rewiring in M1 macrophages by targeting aconitase 2 and pyruvate dehydrogenase","volume":"11","author":"Palmieri","year":"2020","journal-title":"Nat. Commun.."},{"key":"10.1016\/j.molimm.2025.04.016_bib88","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-2600(18)30077-8","article-title":"Safety and immunogenicity of the novel Tuberculosis vaccine ID93 +\u2009GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial","volume":"6","author":"Penn-nicholson","year":"2018","journal-title":"Lancet Respir."},{"key":"10.1016\/j.molimm.2025.04.016_bib89","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin. Infect. Dis.."},{"key":"10.1016\/j.molimm.2025.04.016_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2014.00180","article-title":"Functional signatures of human CD4 and CD8 T cell responses to Mycobacterium tuberculosis","volume":"5","author":"Prezzemolo","year":"2014","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib91","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nrd2224","article-title":"More than one reason to rethink the use of peptides in vaccine design","volume":"6","author":"Purcell","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.molimm.2025.04.016_bib92","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nm859","article-title":"Recombinant BCG exporting ESAT-6 confers enhanced protection against Tuberculosis","volume":"9","author":"Pym","year":"2003","journal-title":"Nat. Med.."},{"issue":"12","key":"10.1016\/j.molimm.2025.04.016_bib93","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004009","article-title":"Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes","volume":"3","author":"Ren","year":"2008","journal-title":"PloS One"},{"key":"10.1016\/j.molimm.2025.04.016_bib94","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/ije\/22.6.1154","article-title":"Protective effect of BCG against Tuberculous meningitis and miliary Tuberculosis: a meta-analysis","volume":"22","author":"Rodrigues","year":"1993","journal-title":"Int. J. Epidemiol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib95","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1586\/erv.11.28","article-title":"Tuberculosis vaccines in clinical trials","volume":"10","author":"Rowland","year":"2012","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.molimm.2025.04.016_bib96","first-page":"432","article-title":"Combined use of Mycobacterium tuberculosis \u2013 specific CD4 and CD8 T-cell responses is a powerful diagnostic tool of active Tuberculosis","volume":"60","author":"Rozot","year":"2015","journal-title":"Brief. Rep."},{"key":"10.1016\/j.molimm.2025.04.016_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fmicb.2018.00602","article-title":"miRNAs in Tuberculosis: new avenues for diagnosis and host-directed therapy","volume":"9","author":"Sabir","year":"2018","journal-title":"Front. Microbiol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0228381","article-title":"The effect of adjuvants and delivery systems on Th1, Th2, Th17 and Treg cytokine responses in mice immunized with Mycobacterium tuberculosis-specific preoteins","volume":"15","author":"Safar","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.molimm.2025.04.016_bib99","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coi.2014.06.003","article-title":"Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis","volume":"29","author":"Sakai","year":"2014","journal-title":"Curr. Opin. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib100","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.4049\/jimmunol.1400019","article-title":"Cutting Edge: Control of Mycobacterium tuberculosis infection by a subset of lung parenchyma\u2013homing CD4 T cells","volume":"192","author":"Sakai","year":"2014","journal-title":"J. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib101","first-page":"1","article-title":"In vitro evaluation of eudragit matrices for oral delivery of BCG vaccine to animals","author":"Saleem","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.molimm.2025.04.016_bib102","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1016\/j.celrep.2017.03.007","article-title":"Th1 Differentiation drives the accumulation of intravascular, non-protective CD4 T cells during Tuberculosis","volume":"18","author":"Sallin","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.molimm.2025.04.016_bib103","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2021.667206","article-title":"Monocyte and macrophage miRNA: potent biomarker and target for host-directed therapy for Tuberculosis","volume":"12","author":"Sampath","year":"2021","journal-title":"Front. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib104","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/14760584.2019.1552140","article-title":"Current approaches toward identifying a correlate of immune proection from Tuberculosis","volume":"18","author":"Satti","year":"2019","journal-title":"Expert Rev. Vaccin."},{"key":"10.1016\/j.molimm.2025.04.016_bib105","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.4049\/jimmunol.174.7.4210","article-title":"Cross-talk between CD14 and complement receptor 3 promotes phagocytosis of mycobacteria: regulation by phosphatidylinositol 3-kinase and cytohesin-1","volume":"174","author":"Sendide","year":"2005","journal-title":"J. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib106","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.immuni.2010.09.017","article-title":"Reverse vaccinology; developing vaccines in the era of genomics","volume":"33","author":"Sette","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.molimm.2025.04.016_bib107","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.molimm.2018.03.007","article-title":"In silico design of Mycobacterium tuberculosis epitope ensemble vaccines","volume":"97","author":"Shah","year":"2018","journal-title":"Mol. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib108","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.molimm.2016.04.014","article-title":"A novel dendritic cell-targeted lentiviral vector, encoding Ag85A-ESAT6 fusion gene of Mycobacterium tuberculosis, could elicit potent cell-mediated immune response in mice","volume":"75","author":"Shakouri","year":"2016","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib109","first-page":"1","article-title":"An immunoinformatics approach to design a multi-epitope vaccine against Mycobacterium tuberculosis exploiting secreted exosome proteins","volume":"11","author":"Sharma","year":"2021","journal-title":"Sci. Rep.."},{"key":"10.1016\/j.molimm.2025.04.016_bib110","first-page":"1","article-title":"Efficacy and safety of Mycobacterium indicus pranii as an adjunct therapy in category II pulmonary Tuberculosis in a randomized trial","author":"Sharma","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molimm.2025.04.016_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2021.105017","article-title":"Immunoinformatics analysis of antigenic epitopes and designing of a multi-epitope peptide vaccine from putative nitro-reductases of Mycobacterium tuberculosis DosR","volume":"94","author":"Shiraz","year":"2021","journal-title":"Infect. Genet. Evol.."},{"issue":"12","key":"10.1016\/j.molimm.2025.04.016_bib112","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.4049\/jimmunol.172.12.7618","article-title":"Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein","volume":"172","author":"Skeiky","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib113","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1017\/S002217240006945X","article-title":"BCG vaccination of children against Leprosy in Uganda: final results","volume":"87","author":"Stanley","year":"1981","journal-title":"J. Hyg. (Lond. )."},{"key":"10.1016\/j.molimm.2025.04.016_bib114","first-page":"89","article-title":"T cell mediated immunity to Mycobacterium tuberculosis","author":"Stenger","year":"1999","journal-title":"CurrOpinMicrobiol"},{"issue":"3","key":"10.1016\/j.molimm.2025.04.016_bib115","first-page":"200","article-title":"Does the efficacy of BCG decline with time since vaccination?","volume":"2","author":"Sterne","year":"1998","journal-title":"Int J. Tube Lung Dis."},{"key":"10.1016\/j.molimm.2025.04.016_bib116","first-page":"94","article-title":"Protective efficacy of recombinant (Ag85A) BCG Tokyo with Ag85A peptide boosting against Mycobacterium tuberculosis-infected guinea pigs in comparison with that of DNA vaccine encoding Ag85A","volume":"87","author":"Sugawaraa","year":"2006","journal-title":"J. Tube"},{"key":"10.1016\/j.molimm.2025.04.016_bib117","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/eji.200838693","article-title":"Pattern and diversity of cytokine production differentiates between Mycobacterium tuberculosis infection and disease","volume":"39","author":"Sutherland","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib118","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1056\/NEJMoa1909953","article-title":"Final analysis of a trial of M72\/AS01 E vaccine to prevent Tuberculosis","volume":"381","author":"Tait","year":"2019","journal-title":"N. Engl. J. Med.."},{"key":"10.1016\/j.molimm.2025.04.016_bib119","first-page":"37","article-title":"The role of dendritic cells in Mycobacterium tuberculosis infection","author":"Taylor","year":"2012","journal-title":"Virulence"},{"key":"10.1016\/j.molimm.2025.04.016_bib120","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nature07781","article-title":"Innate immune recognition of infected apoptotic cells directs T H 17 cell differentiation","volume":"457","author":"Torchinsky","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.molimm.2025.04.016_bib121","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1084\/jem.20141520","article-title":"Interleukin 27R regulates CD4+\u2009T cell phenotype and impacts protective immunity during Mycobacterium tuberculosis infection","volume":"212","author":"Torrado","year":"2015","journal-title":"J. Exp. Med.."},{"key":"10.1016\/j.molimm.2025.04.016_bib122","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(06)68507-3","article-title":"Effect of BCG vaccination on childhood Tuberculous meningitis and miliary Tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness","volume":"367","author":"Trunz","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.molimm.2025.04.016_bib123","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.tube.2011.01.003","article-title":"Development of vaccines against Tuberculosis","volume":"91","author":"Tyagi","year":"2011","journal-title":"Tuberculosis"},{"key":"10.1016\/j.molimm.2025.04.016_bib124","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","article-title":"Phase 2b controlled trial of M72\/AS01 E vaccine to prevent Tuberculosis","volume":"379","author":"Van Der Meeren","year":"2018","journal-title":"N. Engl. J. Med.."},{"key":"10.1016\/j.molimm.2025.04.016_bib125","doi-asserted-by":"crossref","DOI":"10.1177\/2058738419840241","article-title":"CD3, CD4, CD8, CD19 and CD16\/CD56 positive cells in Tuberculosis infection and disease: peculiar features in children","author":"Venturini","year":"2019","journal-title":"Int J. Immunopathol. Pharm."},{"key":"10.1016\/j.molimm.2025.04.016_bib126","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1194\/jlr.M400308-JLR200","article-title":"Mycobacteria use their surface-exposed glycolipids to infect human macrophages through a receptor-dependent process","volume":"46","author":"Villeneuve","year":"2005","journal-title":"J. Lipid Res."},{"issue":"3","key":"10.1016\/j.molimm.2025.04.016_bib127","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2567.2004.01903.x","article-title":"Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and Bacille Calmette-Guerin","volume":"112","author":"Vordermeier","year":"2004","journal-title":"Immunology"},{"key":"10.1016\/j.molimm.2025.04.016_bib128","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1128\/IAI.70.6.3026-3032.2002","article-title":"Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine Tuberculosis","volume":"70","author":"Vordermeier","year":"2002","journal-title":"Infect. Immunn."},{"key":"10.1016\/j.molimm.2025.04.016_bib129","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/vaccines12121335","article-title":"Advancements in nanoparticle-based adjuvants for enhanced Tuberculosis vaccination: A review","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.molimm.2025.04.016_bib130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12879-023-08092-4","article-title":"Safety and efficacy of tuberculosis vaccine candidates in low and middle income countries: a systematic review of randomized controlled clinical trials","volume":"23","author":"Wilson","year":"2023","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.molimm.2025.04.016_bib131","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.4049\/jimmunol.1300283","article-title":"Protective CD4 T cells targeting cryptic epitopes of Mycobacterium tuberculosis resist infection-driven terminal differentiation","volume":"192","author":"Woodworth","year":"2014","journal-title":"J. Immunol.."},{"key":"10.1016\/j.molimm.2025.04.016_bib132","unstructured":"World Health Organization Global Tuberculosis Report. Geneva. 2019; ISBN 9789241565714."},{"key":"10.1016\/j.molimm.2025.04.016_bib133","unstructured":"World Health Organization Global Tuberculosis Report. Geneva. 2022; ISBN 978-92-4-006172-9."},{"key":"10.1016\/j.molimm.2025.04.016_bib134","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41385-019-0226-5","article-title":"Therapeutic host-directed strategies to improve outcome in Tuberculosis","volume":"13","author":"Young","year":"2020","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.molimm.2025.04.016_bib135","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.nano.2012.02.015","article-title":"Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection","volume":"8","author":"Yu","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.molimm.2025.04.016_bib136","doi-asserted-by":"crossref","first-page":"4164","DOI":"10.1128\/IAI.69.6.4164-4167.2001","article-title":"Gp96-Peptide vaccination of mice against intracellular bacteria","volume":"69","author":"Zugel","year":"2001","journal-title":"Infect. Immun."}],"container-title":["Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025001130?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161589025001130?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T04:14:14Z","timestamp":1749269654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161589025001130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":136,"alternative-id":["S0161589025001130"],"URL":"https:\/\/doi.org\/10.1016\/j.molimm.2025.04.016","relation":{},"ISSN":["0161-5890"],"issn-type":[{"value":"0161-5890","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Goals and strategies in vaccine development against tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Molecular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molimm.2025.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}